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Introduction
The predominant view of cancer aetiology is that the root 
cause lies at the genomic level, perhaps facilitated by expo-
sure to radiation or toxic chemicals in the environment or 
diet. However, there are few, if any, single genetic changes 
which can generate the full picture of increased cell pro-
liferation, motility, migration, extracellular matrix metabo-
lism and tissue penetration. Rather, it is more likely that 
these various facets of oncogenesis involve a series of 
changes in different metabolic pathways. This view has 
been proposed and argued in detail previously with the con-
clusion that five or six steps are required, probably in a spe-
cific sequence, for a cell to acquire an adequate spectrum of 
oncogenic properties to generate a malignant cancer [1, 2].
But how might five or six genetic changes to cellular 
pathways arise in a limited number of possible sequences 
such that cells do not trigger apoptosis and are not detected 
by immune surveillance systems? It seems improbable that 
such a cascade of intrinsically unlikely events could occur 
sufficiently frequently to account for the overall human 
cancer rate of 39.6% quoted by the US National Cancer 
Institute (http://www.cancer.gov/about-cancer/what-is-can-
cer/statistics). The statistics would become more realistic if 
one or more of the cellular changes needed for oncogenesis 
were present continually over an extended period of time 
either as a generalised shift in physiological conditions 
or as a maintained or intermittent exposure to an external 
factor in the biological background. Incidental and rela-
tively transient events such as brief exposure to radiation 
or contact with a mutagen might then lead to a long-lasting 
Abstract Several toxins are known which account for the 
ability of some bacteria to initiate or promote carcinogen-
esis. These ideas are summarised and evidence is discussed 
for more specific mechanisms involving chymotrypsin and 
the bacterial chymotryptic enzyme subtilisin. Subtilisin and 
Bacillus subtilis are present in the gut and environment and 
both are used commercially in agriculture, livestock rear-
ing and meat processing. The enzymes deplete cells of 
tumour suppressors such as deleted in colorectal cancer 
(DCC) and neogenin, so their potential presence in the food 
chain might represent an important link between diet and 
cancer. Over-eating increases secretion of chymotrypsin 
which is absorbed from the gut and could contribute to sev-
eral forms of cancer linked to obesity. Inhibition of these 
serine proteases by Bowman–Birk inhibitors in fruit and 
vegetables could account for some of the protective effects 
of a plant-rich diet. These interactions represent previously 
unknown non-genetic mechanisms for the modification of 
tumour suppressor proteins and provide a plausible expla-
nation contributing to both the pro-oncogenic effects of 
meat products and the protective activity of a plant-rich 
diet. The data suggest that changes to farming husbandry 
and food processing methods to remove these sources of 
extrinsic proteases might significantly reduce the incidence 
of several cancers.
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aberration of cell physiology which, superimposed upon 
the distorted background, could lead to cancer. This con-
cept is of fundamental importance in considering cancer 
prevention, as it implies that identifying and eliminating 
just one of the constant, background influences might pre-
vent many cases of carcinogenesis.
Indeed, several recent authors have commented on the 
possible inter-relationships between external, non-genetic 
influences and cancer initiation. Dejea et al. [3] noted that 
“environmental factors clearly affect colorectal cancer inci-
dence but the mechanisms through which these factors 
function are unknown”, while a second group pointed out 
that “the sources and consequences of non-genetic vari-
ability in metastatic progression are largely unknown” [4]. 
It has even been proposed that external influences may be 
more important than genetic abnormalities in the genera-
tion of some cancers [5].
Three areas of research are especially relevant to this 
problem as they focus on the interface between individuals 
and the environment in relation to oncogenesis. These areas 
include the roles of bacteria, of diet and of obesity. How-
ever, despite the intense interest in the influence of these 
factors on cancer, much of the evidence for them is epide-
miological and correlative, with few convincing explana-
tions of how any of these areas could induce cancer devel-
opment. This review is an attempt to bring together recent 
data on the role of bacteria and diet at the cellular level, in 
an attempt to develop an over-arching concept which links 
these factors. Our conclusion not only provides a plausi-
ble and satisfying explanation of these links but also sug-
gests a global strategy which might substantially lower the 
incidence of many cancers in a simple and cost-effective 
manner.
The bacterial microbiome and cancer
General considerations
It has been estimated that over 15% of newly diagnosed 
cancers are attributable to a bacterial cause [6, 7], a con-
cept that was greatly supported by the discovery that many 
gastric cancers can be traced to infection with Helicobac-
ter pylori [8], while links between a single species of bac-
terium and other specific types of tumour have since been 
claimed in a variety of cases [9–11]. However, if there were 
more generalised mechanisms by which microorganisms 
could alter cell function indirectly towards an oncogenic 
state, generating a pool of cells sensitised to subsequent 
molecular damage, the number of tumours caused by such 
indirect actions of microbes could be very much higher.
Experimental studies have confirmed that it is pos-
sible to induce tumours using bacteria including the 
gastrointestinal (GI) microbiota which can be involved 
in oncogenesis indirectly by promoting a generalised 
inflammatory response and immune activation in tis-
sues outside the GI tract. This latter concept is crucially 
important, emphasising that bacterial involvement in can-
cer initiation may not be limited to local tissues—those in 
which the density of microbes is at its highest—but can 
promote oncogenesis in distant tissues [12].
Inflammation, with or without the involvement of bac-
teria, contributes significantly to the initiation and devel-
opment of cancers and plays a major part in the progres-
sion to gastric carcinoma [8]. TNF-α, in particular, has 
established roles in cancer progression in bowel, liver, 
breast and other sites in mice as well as mammary car-
cinomata in humans [13]. Activation of Toll-like recep-
tors (TLRs) by bacterial lipopolysaccharides is the key to 
the initiation of cancer: chronic inflammation in TLR4-
deficient mice fails to induce tumour formation, whereas 
receptor over-expression promotes oncogenesis [14].
In the intestinal mucosa, commensal bacteria play 
a role in maintaining the immune system generation 
of anti-inflammatory T-reg cells [14] (Fig.  1). Hence, 
interfering with the intestinal microbiota can poten-
tially contribute to the development of a proinflamma-
tory state which can, in turn, compromise the integrity of 
the mucosal barrier and lead to a more widespread and 
possibly systemic involvement [15]. Proinflammatory T 
cells, together with macrophages, are largely responsi-
ble for the production of cytokines such as interleukin-1β 
(IL-1β, IL-6, Tumour Necrosis Factor-α (TNF-α) and 
Transforming Growth Factor-β (TGF-β)), each of which 
has been linked with the promotion of oncogenic metabo-
lism. TNF-α in particular has established roles in cancer 
progression in bowel, liver, breast and other sites in mice 
[16]. An association has also been made between levels 
of tissue TNF-α and human mammary carcinomata and 
together with an evidence that anti-inflammatory drugs 
reduce the incidence of breast cancer, this argues for a 
high relevance of inflammation in this disease [17].
The gut microbiota may also be involved in cancer ini-
tiation produced by the impact of stress on the immune 
system (Fig. 2). Normally, exposure of animals to socially 
stressful situations results in increased blood levels of 
inflammatory mediators such as IL-1β, IL-6 and TNF-α 
and epinephrine [18], possibly as part of an acute-phase 
response. Similar stressful situations also altered the bal-
ance of microorganisms in the gut, and the immune acti-
vation produced by stress was prevented by removing the 
gut microbiota using high-dose antibiotics [19]. This not 
only highlights the sensitivity of the intestinal microbiota 
to environmental factors such as stress, but also indicates 
that the microbes are intimately involved in triggering the 
immune response to stress in the host mammal.
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Microbial balance
The gastrointestinal (GI) microbiota account for around 
90% of the cells present in the human body, but the com-
position of the microbiome varies significantly between 
individuals. There is good evidence that an important influ-
ence on oncogenesis is the balance between the several 
thousand species of bacteria which comprise the micro-
biome. Although the micro-flora and micro-fauna of an 
individual remain stable throughout adult life, they can be 
greatly altered by disease, dietary changes, stress or pat-
terns of antibiotic use [20]. The ability of antibiotics to 
change the balance of organisms in the microbiome and the 
incidence of several cancers supports a role for microbiota 
in the development of those cancers [21].
Microorganisms exhibit numerous chemical methods by 
which a degree of ‘communication’ exists between different 
species and strains of bacteria, and between the microbial, 
mucosal and epithelial surfaces within the GI tract. The 
composition of the GI microbiota has been found to resem-
ble that typical of individuals with cancers even before any 
malignancy has been detected, which may indicate that a 
bacterial factor could be among the earliest substances nec-
essary for oncogenesis if—as predicted above—a continual 
baseline distortion of function is required upon which more 
transient perturbations are superimposed.
In particular, tumours are often associated with a lesser 
diversity of microbial species than normal, healthy tissue 
[22, 23] and probiotics can alter the overall mucosa-associ-
ated microbial profile. After an examination of the micro-
biota of patients with triple-negative breast cancer (TNBC), 
it was concluded that a ‘microbial signature’ was associ-
ated with the presence of TNBC which was not observed 
in normal tissue [24]. Thus, while individual bacterial 
Fig. 1  Stress can influence the 
interactions between bacteria 
and the host. The experience of 
stress can provoke the produc-
tion of cytokines which act on 
bacteria, and the generation 
of cytokine-like molecules by 
bacteria which affect immune 
cell function in the host. The 
movement of T cells in particu-
lar between the chyme and peri-
intestinal fluids can be affected, 
as well as the balance between 
different T cell subtypes and 
their respective generation of 
cytokines
Fig. 2  Known bacterial proteins and other toxins associated with 
cancer. Bacteria are known to produce several enzymes and smaller 
molecules, including inorganic compounds, which have linked with 
various forms of cancer
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species may have a dominant influence in some cancers, 
the overall microbial spectrum may modify that incidence 
and may, in some cases, mask a bacterial influence in some 
patients which might be a primary cause of disease in oth-
ers. By generating a state of maintained low-level infection 
and inflammation, Enzler et al. [25] found that over 50% of 
the mice tested developed neoplasia but the formation of 
those tumours was prevented by treating the animals with a 
broad-spectrum antibiotic.
Mechanisms of bacterial action
There are detailed reviews of the mechanisms by which 
prokaryotes might influence cancer development [26, 27]. 
A number of chemical substances consumed in the diet, 
generated within the intestine by endogenous enzymic 
activity or produced by the action of bacterial metabolism 
have been linked to the development of cancers, espe-
cially of the intestine (Fig.  2). They include overtly toxic 
and oncogenic compounds such as trimethyl-N-amine 
oxide (TMAO), produced by microbial digestion during 
preparation of processed meat products and linked with 
colorectal cancer [28], while 2-amino-1-methyl-6-phe-
nylimidazo-[4,5-b]-pyridine (PhIP) is associated with the 
consumption of cooked red meat and prostatic cancer. 
Deoxycholic acid (DCA) is a secondary bile acid produced 
by many gut bacteria and has been linked with colon cancer 
promotion [27].
Even when bacteria are involved in their production, 
however, these compounds are likely to be produced by 
many of the species which inhabit the human GI tract. 
Equally, the effects of most of these compounds are non-
specific in their actions, involving physico-chemical modi-
fications of biologically significant host molecules with 
little selectivity in their target sites or mechanisms. Com-
batting insults with this level of randomness would be dif-
ficult to achieve.
Bacterial toxins
More amenable to pharmacological interference are bio-
logically specific bacterial toxins (Fig.  2), although in 
many cases the detailed molecular mechanisms remain 
unclear. Several species of bacteria inhibit or degrade the 
tumour suppressor protein p53, including Helicobacter 
pylori in gastric epithelial cells [29]. Strains of Staphylo-
coccus secrete toxic haemolysins and the Staphylococcal 
Enterotoxins promote proliferation of T cells, inducing 
normal cells to secrete factors that enhance proliferation 
of existing malignant T cells. Salmonella typhi can pro-
duce the protein toxin Virulence Factor A which alters cell 
proliferation directly or by increasing β-catenin expres-
sion [30]. The Bacteroides fragilis toxin (BFT) exists in an 
enterotoxin-producing form which induces inflammatory 
bowel disease and colorectal cancer [31].
Some of these more general toxins are potentially sus-
ceptible to agents which prevent their production, which 
block their binding sites on target molecules, which inter-
rupt any host transduction pathways which are adversely 
hyperactivated, or which promote the activity of pathways 
which are down-regulated. Several of these toxins have 
been linked to the initiation or promotion of oncogenesis 
especially, but not exclusively, in the GI tract. More infor-
mation is becoming available on their sites and mechanisms 
of action [32] and a few examples will be discussed next.
Vacuolating cytotoxin A (VacA)
Helicobacter species are among the bacteria most com-
monly associated with the development of cancer and are 
present in an estimated 50% of people worldwide. The 
stomach and duodenum are the regions most commonly 
involved, with gastritis and peptic ulcers progressing to var-
ious forms of gastric cancer. The main virulence factor pro-
duced by Helicobacter is Vacuolating Cytotoxin A (VacA). 
The binding of VacA to the gastric epithelium results in a 
marked proinflammatory response and increased cell prolif-
eration, which is largely due to the formation of membrane 
porosities with secondary changes in macromolecular oli-
gomerization [33]. It may be that the opening of membrane 
pores causes a disruption of diverse pathways depending on 
cell type and the local environmental conditions. Certainly, 
the production and secretion of VacA is partly dependent 
on local extracellular environment, being enhanced in high-
salt (NaCl) concentrations but depressed by high levels of 
acidity [34].
Cytotoxin Associated Gene A (Caga)
Caga is the fourth most highly expressed protein in H. 
pylori and, accordingly, it has received the most intensive 
interest and investigation. Patients possessing H. pylori 
strains which express Caga are significantly more prone to 
develop gastric cancer than people with non-Caga carrying 
bacteria [35] with carcinogenesis being correlated with the 
amount of virulence gene expression [36]. Increases in the 
virulence of H. pylori induced by iron deficiency and high-
salt consumption produce corresponding increases in can-
cer susceptibility.
Within the stomach, H. pylori cells become adherent 
to the gastric epithelial cells, where they avoid immuno-
logical detection and suppress host defence mechanisms 
locally and then proceed to invade the gastric mucosa. 
He et al. [32] identify the various virulence factors asso-
ciated with these phases of disease, linking Caga and 
VacA expression with the later phases of transition from 
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inflammatory status to oncogenesis. In addition, however, 
it was noted that polymorphisms in the host response 
genes for these factors were also important, including the 
E-cadherin receptors (CDH1) for Caga. Binding of Caga 
occurs at its Caga Multimerization (CM) motif and the 
existence of multiple polymorphisms of the CM prob-
ably accounts for the frequently observed variability in 
efficacy of the toxin. However, it is also recognised that 
there are strain variations in the caga gene promoter 
which affect the generation of some proinflammatory 
mediators such as IL-8 [37].
Caga is produced by the cag pathogenicity island [38] 
which is essential for gastric oncogenesis as it is respon-
sible for inserting the Caga protein into host cells. The 
toxin inhibits PARtitioning-defective 1b (PAR1b), a ser-
ine–threonine kinase also known as Microtubule Affinity-
Regulating Kinase-2 (MARK2), which plays a key role in 
determining cell polarity. The resulting disruption of tissue 
organisation compromises cell stability during prolifera-
tion and facilitates oncogenic transformation. These effects 
are compounded by the induction of proinflammatory pro-
cesses within cells [39]. Another factor in the activity of 
Caga is the induced hypermethylation of tumour suppressor 
genes [40]. Caga increases the phosphorylation of protein 
kinase B (Akt), leading to activation of NFkB, up-regula-
tion of DNA-(cytosine-5)-methyltransferase-1 (DNMT1) 
and tumour suppressor hypermethylation.
A number of other transduction pathways are susceptible 
to interference by Caga leading to disturbances of the epi-
thelial mesenchymal transition (EMT), cell adhesion and 
migration. Among the pathways affected are Src homology 
2-containing protein-tyrosine phosphatase-2 (SHP-2) and 
protein kinase C-related kinase-2 (PRK-2) which is inhib-
ited by Caga [41]. A major role of the former enzyme is 
to regulate the activity of RhoGTPases which are the key 
players in the organisation and maintenance of the cytoskel-
eton. The promotion of EMT is accompanied by increased 
nuclear β-catenin and expression of the Snail1 and ZEB1 
proteins. Although both caga and IL-1β can initiate EMT, 
only Caga increases cell invasiveness.
Sougleri et  al. [42] observed the morphological and 
polarity changes characteristic of EMT in response to Caga. 
Using mutant gastric epithelial cells expressing variant 
forms of Caga with differing numbers of EPIYA (Glu-Pro-
Ile-Tyr-Ala)-binding sites, they noted that phosphorylation 
of those sites mediates the interaction of Caga with SHP-2 
noted above, leading to an elongated cell structure resem-
bling that of the EMT and known as the ‘hummingbird’ 
phenotype. Variants of Caga with multiple EPIYA-bind-
ing sites are more motile and aggressive, showing a much 
greater propensity to induce gastric cancer. The mutant 
cells exhibited corresponding differences in the activation 
of matrix metalloproteinase-3 (MMP-3) with increased 
expression of the EMT markers Snail, ZEB1 and vimentin, 
as well as the stem cell marker CD44 [42].
TGF-β is an important regulator of tissue inflammation, 
but H. pylori Caga-positive cells inhibited TGF-β func-
tion via an interaction between Caga and Smad3 [43]. The 
depression in TGF-β anti-inflammatory activity resulted 
in increased secretion of IL-8 and other proinflammatory 
cytokines.
There are other actions of caga whose relevance to car-
cinogenesis remains uncertain. Caga produces increased 
proliferation, reduced apoptosis and increased secretion 
of extracellular matrix components from renal cells, lead-
ing to renal cancers [44] and it is required for the suppres-
sion by H. pylori of heat shock protein expression [45], an 
important aspect of the host cell response to infection and 
injury.
Importantly, the roles of H.pylori and Caga in disease 
are not confined to the stomach or intestine. The Caga pro-
tein is exported from the bacterial cells, as well as infected 
gastric epithelial cells, in the exosomes thus gaining wide 
distribution via the vascular circulation and potentially pro-
moting carcinogenesis in a range of systemic tissues.
Cytolethal distending toxin (CDT)
Some Gram-negative bacteria including species of Heli-
cobacter, especially those which target the liver such as 
H. pullorum and H. hepaticus, can generate another viru-
lence factor cytolethal distending toxin (CDT) [46]. The B 
subunit (CdtB) of the toxin is the primary damaging ele-
ment and induces NFkB translocation and activation with 
the expression of several proinflammatory markers and 
increased production of Th-17 cells. This proinflamma-
tory spectrum probably underlies the progression to cancer 
formation which has been postulated for CDT [47]. Cer-
tainly, the chronic treatment of cells with CDT generates 
phenotypic changes characteristic of precancerous cells, 
with an increased frequency of mutation, chromosomal 
changes with enhanced genomic instability, p38MAPK 
activation and an increased ability to show anchorage-
independent proliferation. There is also a marked increase 
in β-galactosidase activity (indicating senescence) and the 
production of proinflammatory cytokines including IL-6 
and IL-8 [48]. The overall result is to extend cellular lon-
gevity and greatly enhance the probability of cancer forma-
tion [49].
There is also evidence for degradation by the DNAse 
activity of CDT as well as induced dysfunction of the 
DNA damage response [50]. This is known to occur in 
cells deficient in adenomatous polyposis coli (APC) or the 
p53 tumour suppressor [51]. The effect was claimed to be 
responsible for increasing the genomic instability seen in 
cells lacking APC or p53 and was probably responsible 
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for the ability of the cells to show anchorage-independent 
growth. These factors led to the conclusion that, while there 
was little evidence that CDT could induce cancers directly, 
it would certainly promote the oncogenic consequences of 
APC or p53 mutations [51].
Cytotoxic necrotizing factor-1 (CNF1)
This toxin is produced primarily by the food-borne patho-
gen Escherichia coli, although some strains are normal, 
commensal organisms in the GI tract. At the N-terminus of 
the protein, there is a domain responsible for high-affinity 
binding to its target, with a nearby domain which promotes 
internalisation of the protein into cells [52]. The active site 
of CNF1 lies at the carboxyl terminus and promotes deami-
dation of glutamine in RhoGTPase enzymes. As a result, 
the cycle of GTP hydrolysis is blocked in the active state, 
leaving the target Rho enzymes permanently activated [53]. 
CNF1 can also facilitate the removal and degradation of 
Rho enzymes by increased ubiquitinylation and proteaso-
mal metabolism via the Smurf1 pathway.
Several sites have been identified for the initial bind-
ing of CNF1. One of these is the Lutheran adhesion gly-
coprotein and Basal Cell Adhesion Molecule (Lu/BCAM) 
[54], while a second has been defined as the amino acid 
sequence 720–1014 which binds to the Laminin Precur-
sor Protein p37LRP. A nearby high-affinity site is respon-
sible for the attachment and adhesion of CNF1 to the cell 
membrane. The functional consequence of CNF1 binding 
is an increased cell proliferation and diminished the rate of 
senescence which can facilitate oncogenesis. CNF1 induces 
a proinflammatory phenotype in target cells with activation 
of NFkB, a release of proinflammatory cytokines from epi-
thelial cells and increased cell migration [55].
CNF1 is one of the bacterial toxins whose carcinogenic 
properties are not confined to the GI tract. The toxin can be 
trafficked between cells via extracellular vesicles which are 
similar to, if not identical with, normal exosomes [56]. The 
toxin can therefore pass through the GI wall into other tis-
sues, potentially transmitting its oncogenic activity to dis-
tant regions of the body.
Colibactin
Another toxic factor from E. coli is colibactin, a peptide-
polyketide molecule secreted by group B2 E. coli [57, 58]. 
It is synthesised by a non-ribosomal peptide synthetase-
polyketide synthase (pks) enzyme complex which is found 
in those strains of E. coli that are most often associated 
with GI tract tumours [58]. Colibactin produces significant 
DNA damage which, in addition to inflammatory activ-
ity and the induction of genomic instability, is thought to 
explain its association with cancer [59]. Colibactin possess 
an unique “warhead” responsible for interacting with DNA 
and producing cross-linking and strand breakages [60].
A related mechanism for cancer formation and stabilisa-
tion is the enhancement by colibactin of pathways which 
prolong tumour cell longevity. These include the generation 
of growth factors and senescence-related molecules such as 
microRNA-20-5p. The latter regulates Small Ubiquitin-like 
Modifier (SUMO) proteins with the accumulation of conju-
gates between SUMO and the tumour suppressor p53, lead-
ing to increased growth and proliferation.
Novel bacterial targets: dependence receptors DCC 
and neogenin
Most bacterial products, as discussed above, affect general 
cellular pathways rather than those directly related to the 
cancerous properties of cells. Recent evidence has sug-
gested that a more cancer-specific site—the dependence 
receptors—could be the target of an important group of 
bacterial and mammalian enzymes.
The ‘dependence receptors’ include three proteins which 
have been independently linked with cancer initiation and 
development: Deleted in Colorectal Cancer (DCC), neo-
genin and uncoordinated-5 (unc-5). The initial discov-
ery that the dcc gene exhibited a loss of heterozygosity in 
many cases of colorectal cancer [61] was soon expanded 
with the realisation that similar deficits were seen in many 
other forms of cancer [62]. Abnormally low expression of 
DCC is indicative of poor patient prognosis [63, 64] and 
anti-sense DNA can increase rates of cell proliferation and 
migration [65, 66], whereas transfection with the ectopic 
DCC protein can have the opposite effect [66–68]. Increas-
ing DCC expression even suppresses the pro-metastatic 
effects of depleting the tumour suppressor p53 [68].
DCC is a receptor for the extracellular secreted protein 
ligand netrin and functions as a brake on cellular apopto-
sis in the presence of netrin [69] (Fig. 3). If ambient lev-
els of netrin fall, DCC is permitted to initiate apoptosis, 
thus ensuring that a damaged or isolated cell does not 
continue to exist for long even if it evades immune sur-
veillance (which pro-cancerous cells appear to do at least 
partly by inducing indoleamine-2,3-dioxygenase (IDO) and 
its kynurenine metabolites) [70–72]. Conversely, a loss of 
DCC expression should prevent the initiation of apoptosis 
and allow cancerous cells to proliferate more readily. One 
factor in the suppression of cancer development, there-
fore, is the presence of a correctly functioning netrin-DCC 
axis and in the absence of DCC increased concentrations 
of netrin facilitate tumour formation [73], especially of the 
ovaries and breasts where it regulates mammary epithe-
lial cell development. Netrin expression is also enhanced 
by NFkB, possibly contributing to the well-established 
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association between chronic inflammation and cancer 
development.
Neogenin and Unc-5
A related protein, neogenin shows more than 50% sequence 
identity with DCC [73] and has broadly similar functions, 
with netrins and the family of Repulsive Guidance Mol-
ecules as extracellular ligands. There are important differ-
ences between DCC and neogenin, as in the early stages of 
embryogenesis when DCC expression is high and neogenin 
is low. Nevertheless, a reduction in neogenin expression 
can increase tumour formation by promoting proliferation, 
migration and invasion [74, 75], while over-expression can 
initiate apoptosis [76, 77]. Neogenin has been linked par-
ticularly with the development of mammary cancer [78, 
79].
Finally, the Unc-5 receptor is also a tumour suppressor 
and its depletion from intestinal cells can promote cancer-
ous behaviour [62, 80, 81].
In spite of the very significant role which these three 
dependence receptors play in the balance between apopto-
sis and proliferation, migration and invasion—a role which 
is clearly crucial in oncogenesis—functionally important 
gene mutations have been found relatively infrequently, 
raising the possibility that non-genetic abnormalities may 
underlie cellular dysfunction. One mechanism for that 
might be the recently described down-regulation of their 
expression by serine proteases, described next [82].
Serine proteases (SPs) deplete dependence receptors
Serine protease (SP) enzymes include the bacterial enzyme 
subtilisin and its mammalian equivalent chymotrypsin. 
They are able to modulate cellular communication by act-
ing partly on proteasomal enzymes [83]. Recent work has 
found that both subtilisin and chymotrypsin are able to 
deplete the dependence receptors DCC and neogenin (and 
to a lesser degree Unc-5C) from mammalian cells [83–85], 
inducing cancerous properties such as increased migration 
[82]. This effect of SPs was selective, with several other 
Fig. 3  A schematic illustration of how serine proteases might link 
diet and obesity to cancer susceptibility. The Panel 1 inset (1  A) 
illustrates the presence of the dependence receptors (DRs) DCC and 
neogenin, which possess the intrinsic ability to initiate cell death. 
This activity is normally suppressed by the interaction of netrin with 
these receptors (1B) which restrains their apoptotic drive and allows 
cell survival. Conversely, the DRs inhibit the proliferative and migra-
tory drive of netrin and if the DRs are blocked or deleted, netrin 
directly drives the cells to proliferate (1 C). The main part of Panel 
1 shows subtilisin (blue arrows) in the intestine, arising from com-
mensal bacteria or dietary intake in meat products, with chymotrypsin 
(grey arrows) as a digestive enzyme potentially in elevated concen-
trations as a result of over-eating. Both are absorbed into the blood 
from where they can reach most organs and tissues. Panel 2 illustrates 
the effect of subtilisin and chymotrypsin in the tissues, depleting 
DCC and neogenin (2 C) and permitting the netrin drive to over-pro-
liferation and migration. This will promote the progression of cells 
to increasingly advanced stages of oncogenesis. The lower panel 3 
indicates the consumption of Bowman–Birk inhibitors in the diet and 
their absorption into the circulation and tissues where they can block 
the protease-mediated removal of the DRs, allowing their continued 
suppression of the netrin oncogenic drive (3 C)
▸
2634 T. W. Stone, L. G. Darlington 
1 3
proteins being resistant to the enzymes at concentrations 
10- to 100-fold higher than those which affected DCC and 
neogenin. Subtilisin was active at nanomolar concentra-
tions on SH-SY5Y human neuroblastoma cells and both 
subtilisin and chymotrypsin were active on SH-SY5Y cells, 
CaCo-2 human colorectal cancer cells, MCF-7 and MDA-
MB-231 human mammary adenocarcinoma cells as well 
as on freshly isolated tissue, in which the levels of DCC 
are much higher than in cancer-derived cell lines. Since the 
cancer-derived cells expressed little DCC, the dcc gene was 
transfected into SH-SY5Y and MCF-7 cells. Subtilisin then 
decreased the expression of the ectopic DCC as well as the 
intrinsic neogenin in both cell lines. Both subtilisin and 
chymotrypsin significantly increased the migration of cells 
producing scratch closure in human MCF-7 breast cancer 
cells without any confounding changes in cell proliferation 
[82].
These results led to our formulating a new potential 
mechanism linking diet, bacteria, obesity and cancer (Fig, 
3). Animals (including humans) are potentially exposed to 
subtilisin, firstly because it may be present in dietary prod-
ucts and secondly because Bacillus subtilis and related 
bacteria which secrete subtilisin are present in the intes-
tine, the food chain and in cleaning materials (see below). 
Furthermore, chymotrypsin and trypsin levels are increased 
in individuals eating a high-meat diet and in obesity. In 
all these situations, the subtilisin or chymotrypsin may 
potentially deplete DCC and neogenin from cells of the 
GI tract, immune system cells in contact with the GI tract 
and in other tissues to which the enzymes have access after 
absorption. The following sections of this review will pre-
sent more detailed information on these assertions.
Subtilisin in the environment and diet
Subtilisin is an alkaline serine protease and is classified 
as a chymotrypsin-like enzyme by virtue of its substrate 
specificity which overlaps that of chymotrypsin itself and 
is amenable to blockade by chymostatin. Conversely, many 
chymotrypsin-like enzymes are referred to collectively as 
subtilases and some have been linked with cancer initiation 
[86, 87].
Subtilisin is produced primarily by Bacillus species, 
although the term includes almost identical molecules such 
as subtilisin BPN from B. amyloliquefaciens and subtilisin 
Carlsberg from B. licheniformis. Closely related enzymes 
with similar substrate specificities are secreted by other 
bacteria including Streptomyces spp. and Cryptosporidium 
spp but are also produced by some fungi and yeasts such 
as Aspergillus species, Cryphonectria parasitica, Tricho-
derma reesei, which secretes a subtilisin-like protease in 
large quantities, and the ascomycete Fusarium equiseti.
Bacillus subtilis is a natural member of the microbiota 
present in the human GI tract, being isolated from ileal 
biopsies and faecal samples [88]. The bacteria and spores 
resist destruction in the stomach and intestine [89] and the 
surviving spores germinate in the intestinal lumen [90]. It 
is likely that B. subtilis remains a long-term inhabitant of 
the human intestine since it can exist aerobically (as in the 
atmosphere or soil) or anaerobically (as in the intestine) 
where it can survive and produce spores in the presence of 
nitrite or nitrate to furnish redox interacting ions as electron 
acceptors.
In the upper small intestine, the pH of many mammals 
including humans is around 6, but this rises as food pro-
ceeds through the lumen, reaching over pH 7 in the large 
bowel and sometimes exceeding pH 8 in patients with 
ulcerative colitis, a condition which can precede the devel-
opment of colorectal cancer. Since subtilisin is an alkaline 
serine protease (optimal activity at pH around 8), it will 
function best in the large intestine and acidification of the 
bowel contents should inhibit the enzyme and its oncogenic 
properties on the dependence receptors [91]. A fibrous diet, 
which also tends to produce a more acid pH in the bowel, 
should contribute to the protective effects of dietary fibre 
and cereals against cancer [92] mediated by alkaline serine 
proteases.
Interestingly, high extracellular concentrations of salts 
increase the synthesis and secretion of several exoproteases 
from bacteria, including subtilisin and related enzymes 
[93], a phenomenon which may contribute to the high inci-
dence of gastric cancers associated with the high-salt intake 
of the Japanese diet [94].
Industrial sources of subtilisin
As an enzyme with high stability at a wide range of tem-
perature and acidity, subtilisin has found widespread com-
mercial and industrial use. The bacterium B. subtilis shows 
a similar tolerance of the environment and of radiation than 
most common microorganisms. As a result, B. subtilis is 
found widely distributed in the environment and is found in 
high densities in soil.
In the food industry, subtilisin is used to tenderise meats 
to improve taste and texture and to facilitate packaging 
(approximately 1000 tonnes of the enzyme were used in 
Europe in 2007; [95]). It is also one of the several proteases 
used to digest those parts of animal carcasses that are unfit 
for human consumption and which may be used to feed 
animal livestock or to produce fertilisers [96], both uses 
of which might lead to subtilisin in the human food chain 
and, potentially, an increase in cancers in farm animals and 
humans.
In addition to these specialised industrial uses of sub-
tilisin, the enzyme is a constituent of many detergent 
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preparations used for cleaning in domestic and commercial 
establishments and for a variety of other industrial applica-
tions. The website of the US Household Products Database 
lists well over 100 items used in household cleaning which 
contain subtilisin (https://householdproducts.nlm.nih.gov/
cgi-bin/household/brands?tbl=chem&id=1699). New vari-
ations in the structure of subtilisin are constantly being 
developed and patented for increased stability under atypi-
cal conditions of temperature and acidity in order to widen 
their range of industrial uses and markets.
Probiotics
The increasing use of probiotic preparations in agriculture, 
farming and medicine is being accelerated by the need to 
identify alternatives to conventional antibiotics to mod-
ify the GI microbiome towards a healthier mix and thus 
to promote animal growth. The Bacillus family includes 
several species found in probiotic preparations for use by 
humans and farm animals [97–99] including B. subtilis, B. 
amyloliquefaciens and B. licheniformis, all of which secrete 
subtilisin and which efficiently colonise the intestine with 
live bacteria, providing a valuable commercial advantage 
but with a potential oncogenic risk [89].
Whatever the gains in animal husbandry, there are risks 
associated with the handling of the ultimate product in the 
form of meat or carcasses. Marouani-Gadri et  al. [100] 
examined the bacterial contamination of surfaces in a meat 
processing plant. Even after cleaning and disinfection, sig-
nificant numbers of several bacterial species could be iso-
lated, the most prominent being Staphylococcus and Bacil-
lus species. Intensive rearing of animals in confined spaces 
is likely to exacerbate this problem. Beyond the food pro-
duction industry, B. subtilis and related strains have been 
identified as contaminants in commercial fast food outlets 
[101].
Protease absorption and systemic cancers
While the GI tract would seem to be the tissue most likely 
to be traumatised by chymotrypsin or subtilisin in the 
diet or microbial secretions, it has long been recognised 
that large proteins including trypsin and chymotrypsin 
are absorbed from the GI tract [102–105] and reach the 
blood in physiologically relevant concentrations [105–107] 
(Fig.  3). Indeed, both proteins are far smaller (~27  kDa) 
than ferritin (~500 kDa) which is also absorbed [107]. Con-
sequently, any increase in the GI levels of chymotrypsin or 
subtilisin, caused by obesity or dietary intake, respectively, 
will be reflected systemically, potentially generating an 
increased risk of cancer incidence in most internal organs.
Other chymotryptic proteases and subtilases
There are several other chymotryptic proteases in mam-
mals in addition to those described above. A recent report 
indicates that neutrophils are required for the development 
of mammary tumours produced by bacteria [108]. The oral 
administration of Helicobacter hepaticus to mice usually 
resulted in the formation of mammary tumours but not if 
the blood was depleted of neutrophils by injections of the 
anti-Ly-6G antibody. One explanation of this could lie in 
the fact that inflammatory neutrophils, attracted to sites of 
tissue inflammation or infection and assisted by local mast 
cells, release large quantities of chymotryptic proteases, 
especially chymase and cathepsin G. These enzymes could 
then deplete mammary cells of DCC or neogenin [82], pro-
moting the formation of tumours. This explanation fits per-
fectly with another recent observation that inflammation of 
the lungs can facilitate the formation of metastases which 
are dependent on serine proteases released from neutro-
phils [109].
A major argument favouring a role for serine proteases 
in cancer development is that they are specifically suscep-
tible to inhibition by the Bowman–Birk inhibitors found 
in many dietary fruits and vegetables, the topic addressed 
below.
Dietary plants and protection against cancer
After several decades of claims and counter-claims about 
the potential health benefits of foods or different plant 
species, some general principles are appearing for those 
plants that provide the strongest evidence. This review is 
focussed on general targets for tumour suppression, indicat-
ing specific compounds only where there is a strong bias 
of activity for a particular mechanism or if there is a target 
unique to that compound. Most of the following informa-
tion relates to the anti-cancer activity of around ten major 
compounds (with their primary plant source): curcumin 
(turmeric), lycopene (tomato), resveratrol (red grapes, pea-
nuts), genistein (soybean), sulforaphane (4-methylsulfinyl 
butyl isothiocyanate) and indole-3-carbinol (I3C and its 
dimerised metabolite, 3,3′-di-indolylmethane, DIM) (Bras-
sica spp.), epigallocatechins (green tea), 6-gingerol (gin-
ger), ellagic acid (pomegranate), β-carotene (carrots), dial-
lyl sulphide and S-allyl cysteine (allium), allicin (garlic). In 
addition to these, the presence of Bowman–Birk inhibitors 
(see below) in a range of fruit and vegetables may be espe-
cially relevant in explaining the importance of a balanced 
meat and vegetable diet in which the plant component can 
block the effects of the serine proteases discussed above 
[82].
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Cell cycle
Suppressing the cell cycle inevitably leads to the loss of 
tumour growth and, potentially, to the reduction of metas-
tasis. Curcumin (diferuloylmethane) causes cycle arrest 
by up-regulating the tumour suppressors p53 and p21, a 
mechanism shared with compounds such as sulforaphane, 
other isothiocyanates, β-carotene, and N-methoxyindole-
3-carbinol (NI3C) [110–112] leading to delays in the G0/
G1 or G1/S transitions of the cycle.
Cessation of the cycle in the G2/M phases follows the 
activation of c-jun N-terminal kinase (JNK) and the p38 
MAPK pathway. Sulforaphane normally halts cell progres-
sion in the G0/G1 and G2/M phases, but can stop prolifera-
tion in G1/G2 [113].
The cyclins and related proteins as well as the associated 
checkpoint kinases have been discussed in detail [114]. 
The cyclin-dependent kinases (cdk), especially cdk2 and 
cdk6, are particularly sensitive to inhibition by I3C and 
DIM and lead to cycle halting at the G2/M transition [115, 
116]. However, the precise identity of the cyclins affected, 
the nature of their interactions and the results of interfering 
with them appear to vary substantially between cells of dif-
ferent cancer types. The cyclins are direct targets of several 
agents. Some flavonoids inhibit cdk4, cdk6 in addition to 
direct actions on cyclin D subtypes [117, 118], while oth-
ers such as quercetin inhibit genes that induce mitosis, such 
as polo-like kinase-1 (PLK1) and cell division cycle pro-
tein 20 homolog (CDC20). Quercetin also has important 
actions on cell growth as well as proliferation [119]. The 
isothiocyanates, present in many species of Brassica, sup-
press expression of cdk1 and cdc25, partly by promoting 
their degradation, causing cycle stasis in G2/M. Resveratrol 
can arrest cells in the G1/S phase and induce apoptosis by 
interfering in cyclin–cdk interactions.
Cell death
Most of the pathways attacked by natural anti-cancer com-
pounds result in a suppression of cell growth and prolifera-
tion, usually accompanied by the induction of apoptosis or 
autophagy. The Wnt/β-catenin pathway and associated pro-
teins such as glycogen synthase kinase-3β (GSK-3β) and 
adenomatous polyposis coli (APC) are among the most fre-
quently altered cellular molecules and they are influenced 
by many of the dietary compounds showing anti-cancer 
activity.
β-catenin promotes the expression of cell proliferation-
related target genes, such as c-myc and cyclin D1 [120]. 
Curcumin suppresses the expression of p300 protein [121], 
an accessory molecule for the activation of oncogenic 
molecules by the Wnt/β-catenin pathway, thus inhibit-
ing β-catenin-related transcription and depressing cell 
growth and proliferation. In the same work, c-myc was 
inhibited, contributing to cell cycle stasis in G2/M along 
with increased levels of apoptosis. Genistein up-regulates 
GSK-3β which, by retaining β-catenin in complexation 
with APC, prevents its nuclear translocation and gene acti-
vation [122]. DIM achieves the same result by enhancing 
phosphorylation of β-catenin, preventing its passage into 
the nucleus.
While the promotion of apoptosis is well established, 
there is less information on autophagy as a cancer-limiting 
mechanism. Certainly, many compounds of interest do tar-
get pathways implicated in autophagy, including the Ras-
Raf/MAPK pathway, the Pi3KCI/Akt/mTOR sequence, 
FOXO1 signalling and p53. Antagonistic interactions also 
exist between pro- and anti-apoptotic pairs. The outstand-
ing example of this is the Bcl-2 and Bcl-2 associated X 
protein (Bax) combination, the former apoptosis inhibitor 
being in competition with Bax and related proteins. Activ-
ity in the Bcl-2/Bax system is often initiated or enhanced 
under abnormal (stressful) conditions. Apoptosis is regu-
lated by the actions of these proteins on the caspase cas-
cade [123]. Bcl-2 and Bcl-extra large (Bcl-XL) can play 
key roles by mediating autophagic signalling pathways. 
Tumour suppressor p53 plays distinct roles in autophagy 
which depend on its subcellular localization. Nuclear p53 
can promote autophagy by interacting with sestrins 1/2, but 
in the cytosolic compartment p53 inhibits autophagy by 
activating Bax.
As with many cellular functions, the existence of path-
ways critical to cell viability is accompanied by mecha-
nisms to balance those functions, preventing cell damage 
or loss which might result from uncontrolled overactivity. 
Hence, the Inhibitors of Apoptosis Proteins (IAP) form 
several families of dietary targets whose suppression shifts 
the balance of activity in favour of apoptosis. Most of these 
proteins prevent caspase activation or promote their inacti-
vation and degradation [123]. Sulforaphane down-regulates 
the anti-apoptotic gene Bcl-2 and the X-linked inhibitor of 
Apoptosis Protein (XIAP) [124].
The mammalian Target of Rapamycin (mTOR) is a neg-
ative regulator of autophagy in cancer cells and its phos-
phorylation mTOR is inhibited by curcumin and related 
compounds. The PI3KCI-Akt, Ras-Raf-1-MEK1/2-ERK1/2 
signalling pathways present a route to mTORC1 which is, 
alternatively, susceptible to inhibition by the liver kinase 
B1 (LKB1)-AMPK complex [125]. The latter assembly 
down-regulated the drive to autophagy which is also influ-
enced by the upstream interacting proteins PI3KCI-Akt. 
Both genistein and curcumin inhibit the Akt pathway, pos-
sibly as a result of inhibitory actions on src-family kinases, 
while I3C inactivates Akt via the inhibition of Pi3K expres-
sion and the loss of Akt phosphorylation [126]. Rest-
ing activity of PI3KCIAkt- mTORC1, or Akt alone, can 
2637Microbial carcinogenic toxins and dietary anti-cancer protectants 
1 3
normally be responsible for initiating autophagy, possibly 
making their activation by dietary compounds easier than 
inducing activity ab initio.
A major trigger for autophagy is the forkhead O tran-
scription factor FOXO1. Chronically abnormal conditions 
in the cellular environment such as those likely to pertain 
during chronic inflammation induce FOXO1 to dissoci-
ate from its binding to sirtuin-2 (SIRT2). The subsequent 
acetylation state of FOXO1 is dependent on the balance of 
activity in epigenetic regulators such as histone acetylases 
and de-acetylases. The acetylated form of FOXO1 binds to 
the E1 accessory protein of Autophagy-related protein-7 
(Atg7) to form the complex which regulates the initiation 
of autophagy [127].
The related target FOXO3 modulates the Akt/Wnt cas-
cade discussed earlier. The binding of FOXO3 to the andro-
gen receptor promoter is believed to be critical in prostate 
cancer and that binding is prevented by DIM. Other com-
pounds affecting Akt, noted above, will also modify activ-
ity in the Akt/FOXO3a/GSK-3β/AR pathway [128]. The 
ellagitannin group of compounds shows beneficial effects 
against colon carcinogenesis by inhibiting Wnt signalling 
and by suppressing the PI3K/Akt pathway.
Cell demise, producing a loss of cancerous cells, can 
also be orchestrated by receptors responding to external 
ligands such as TNF-α. In most cases, cell death is medi-
ated by the caspase cascades. Benzyl isothiocyanate and 
sulforaphane are examples of Brassica compounds able to 
promote this pathway to cancer cell death production [129].
Inflammation
Chronic inflammation is a major risk factor for the initia-
tion of cancer. The reduced activation of MAPK by many 
dietary compounds noted above generates a secondary 
loss in expression of inflammation-related proteins such as 
cyclo-oxygenase-2 (COX-2) and interleukin-6 (IL-6), both 
of which can affect the production of TNF-α [130]. Many 
members of the flavonoid class, especially the flavonols, 
can decrease the expression of proinflammatory mediators 
such as IL-1α, IL-4, inducible nitric oxide synthase (iNOS) 
and TNFα directly [118].
The inflammation driver Nuclear Factor κ-light-chain-
enhancer of activated B cells (NF-κB) is frequently acti-
vated either directly or by inhibition of its inhibitory 
component (inhibitor of kB kinase, IKK). The isoflavone 
genistein inhibits Notch signalling which results in the 
suppression of NFkB activity [131]. Curcumin and many 
flavonoids in food also inhibit NFkB and its downstream 
targets including cyclin D1, COX-2, MMP-9 and the 
Bcl-2 / Bcl-xL pathway, by down-regulating the expres-
sion of IKK. I3C and DIM also inhibit NFkB binding to 
DNA [118, 132]. Resveratrol prevents the activation of 
NF-kB and several inflammation-related genes with par-
ticularly marked suppression of iNOS [133]. The action 
of compounds on these pathways includes an inhibi-
tion of activation in response to external stimuli such 
as lipopolysaccharides (LPS) from bacterial infections. 
Flavonoids in fruits and vegetables are good regulators 
of NF-B expression. Their anti-inflammatory actions 
are enhanced by inhibiting ornithine decarboxylase and 
COX-2 activity as well as matrix metalloprotease expres-
sion [118].
Cell migration
An important class of enzymes intimately involved in cell 
migration is that of protein kinases. For abnormally active, 
cancerous cells, these provide a plethora of targets for 
plant-based compounds. Curcumin, I3C and DIM inhibit 
p38 MAPK and reduce the activity of several of the MAPK 
kinase kinase (MEKK) enzymes and JNK proteins [134]. 
Resveratrol also induces apoptosis by activation of MAPK, 
causing caspase activation and cell death [115, 130].
A number of anti-tumour compounds affect the endothe-
lial mesenchymal transition (EMT), resulting in the sup-
pression of cell migration and metastasis formation. Sul-
foraphane increases the epithelial expression of E-cadherin 
and so stabilises cells in their resting state, inhibiting 
metastasis. This is accompanied by a reduced expression of 
the Zinc finger E-box-binding homeobox  1 (Zeb1) which 
is often used as a characteristic marker of the early stages 
of EMT. Sulforaphane inhibits migration and invasion 
partly by activating ERK1/2 and downstream signalling. 
This leads to up-regulation of E-cadherin, the stabilisation 
of cell state and the suppression of EMT. Suppression of 
activity in the Wnt / GSK3β / β-catenin pathway (above) 
will contribute to the prevention or interruption of EMT 
and of cell migration.
An important aspect of tumour expansion and metastasis 
formation is the breaking of barriers to permit the ingress 
of invading cells. Among the most commonly targeted 
proteins in this respect are the matrix metalloproteases 
(MMPs), whose expression can be promoted by a variety 
of mechanisms including the increase of Notch signalling, 
for example, by sulforaphane which promotes MMP-9 
expression.
Combining several compounds from these various 
groups, in a well-balanced diet, should bring substan-
tial improvements to their efficacy as anti-cancer agents. 
Thus, combinations of epigallocatechin-3-gallate and 
sulforaphane (Brassica spp.) produced markedly greater 
improvement in the inhibition of breast cancer cell growth 
and progression of the disease in  vivo than either com-
pound alone [135, 136].
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Aryl hydrocarbon receptor (AHR)
A different series of molecular targets for plant compounds 
are those associated with the metabolism of key regulators 
of cell function. Several dietary compounds can induce or 
enhance the activity of enzymes responsible for destroying 
foreign and toxic compounds, which would include some 
of the bacterial products and cooking-related toxins dis-
cussed earlier in this review. An example is the effect of 
sulforaphane to inhibit cytochrome P450 Phase I enzymes 
which normally catabolise heterocyclic amines produced 
by cooking into carcinogenic derivatives that interact with 
nucleic acids and disrupt gene transcription [137, 138]. 
The same compounds induce the expression of phase II 
metabolic enzymes which complex with potentially toxic 
compounds, especially those with marked pro-oxidant and 
mutagenic properties, to catabolise them for excretion.
One receptor-based mechanism is proving to be a poten-
tially significant target of dietary compounds. Although 
long recognised as a xenobiotic sensing receptor, the Aryl 
Hydrocarbon Receptor (AHR) is now known to inhibit 
tumour development, partly because of its regulation of 
innate immune surveillance and response mechanisms. 
This activity is either constitutive or maintained by local 
levels of endogenous agonists such as kynurenine, since 
deletion of AHRs increases the entry of breast cancer cells 
into cycle stasis [139]. The dietary indole derivatives IC3 
and DIM can activate the receptor to produce both a direct 
inhibition of cell proliferation and an inhibition of oestro-
gen-dependent tumorigenesis [140]; its possible activation 
by other dietary compounds is under intense investigation.
Serine protease inhibitors: the Bowman–Birk Factor
In considering the role of diet in cancer, meat intake rep-
resents only one part of the problem. The other is whether 
the anti-cancer effects of a plant-rich diet [141–143] can 
be explained by the actions of serine proteases (Fig.  3). 
Having discussed the possibility that serine proteases may 
contribute to carcinogenesis by depleting cells of DCC 
and neogenin, it is highly relevant that plants contain sev-
eral serine protease inhibitors, the largest group of which 
is that of Bowman–Birk inhibitors (BBIs) [144–147]. BBIs 
are primarily inhibitors of chymotrypsin, although many 
have a second, independent catalytic site which inhibits 
trypsin. Members of this family occur in a wide range of 
plants including the widely studied inhibitor from soybean 
(Glycine max) as well as lentils, pulses, wheat, potatoes and 
many other edible plants [145]. There are numerous studies 
of the health and anti-cancer activity of BBIs [148], with 
comprehensive reviews of their activities and health ben-
efits including anti-inflammatory and anti-cancer properties 
[144, 145].
Soybeans are not only water-soluble, but can also resist 
boiling for limited periods, with high stability over a range 
of temperatures and acidity in addition to their resistance 
to metabolism in the GI tract. The reports of serine pro-
tease depletion of DCC included the observation that the 
soybean BBI blocked the ability of chymotrypsin to down-
regulate DCC and also blocked the increased migration of 
MCF-7 human breast adenocarcinoma cells produced by 
chymotrypsin [82]. This strongly supports the serine pro-
tease hypothesis and the anti-cancer protective effects of a 
plant-rich diet.
Despite some negative reports [149, 150], studies show 
consistently that some types of meat promote colon car-
cinogenesis in treated animals [151–157]. Similarly in 
human studies, there is a demonstrably higher risk of can-
cer, especially colorectal cancers, following regular and 
frequent meat consumption [158–167]. In one large-scale 
study, a vegetarian diet reduced the risk of colorectal can-
cer by 19% − 29% compared with non-vegetarians, while 
fish-eaters showed a 43% lower risk compared with the 
non-vegetarians [141]. These comparisons were reflected 
in other large cohorts which identified a significant link 
between colorectal cancer and the consumption of pro-
cessed meat [158, 160, 163].
Overall, it seems clear that regular consumption of meat, 
especially of processed meat products, is probably linked to 
several forms of cancer and there are reasons to believe that 
serine proteases might be involved. Conversely, the con-
sumption of a plant-based diet, rich in the protease inhibi-
tory Bowman–Birk compounds, might protect against can-
cer by reducing the contribution of those serine proteases 
to the cancer risk (Fig. 3).
Summary and the potential for prevention
This review has summarised some of the evidence that bac-
teria and their products may be involved in the association 
between a meat-based diet and oncogenesis, emphasising 
the selective effect of two serine proteases in depleting cells 
of the tumour suppressors DCC and neogenin, thus poten-
tially promoting oncogenesis and metastasis. The bacterial 
protease subtilisin and B. subtilis which secretes it, may be 
employed in farm animal husbandry via probiotic adminis-
tration, meat processing and some cleaning products. Their 
possible presence in the food chain and environment may 
predispose some individuals to develop a range of can-
cers. Mammalian chymotrypsin levels in the intestine and 
bloodstream are increased in obese individuals and those 
consuming a high-meat intake, possibly accounting for the 
link between obesity and cancer. The absorption of both 
proteases from the intestine may promote cancer in many 
internal organs as well as the GI tract. Perhaps most impor-
tantly, this mechanism may be part of the continual assault 
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on cells from background, environmental sources, which 
primes some cells to the damage inflicted by more transient 
insults such as a toxin or radiation or which exacerbates the 
oncogenic potential of any genetic abnormality. The con-
sumption of many fruits and vegetables will provide BBIs 
which inhibit serine proteases and may explain the protec-
tive effects of a plant-rich diet.
These concepts require extensive validation and expan-
sion but, if they are correct, the implications for cancer 
prevention might be substantial. At the more difficult level 
of selectively removing specific bacterial sources of ser-
ine proteases, tools to kill the organisms responsible, such 
as species-specific siRNA or anti-sense oligonucleotides 
might be feasible. Certainly similar approaches to block the 
synthesis of subtilisin should achieve a similar objective.
If the importance of subtilisin and related serine pro-
teases on DCC removal and cancer promotion is substanti-
ated, population exposure to serine proteases could be read-
ily produced by modifying agricultural and food processing 
methods, and increasing the intake of purified plant-derived 
enzyme inhibitors such as the Bowman–Birk families. Even 
the simple expedients of more thorough rinsing of kitchen 
and dining implements to remove residual films of bacte-
ria, rinsing of clothing washed in ‘biological’ detergents 
containing subtilisin-like enzymes and the rigorous scrub-
bing of soil from un-peeled root vegetables could reduce 
the levels of domestic contamination by bacteria and their 
serine proteases. Together, such considerations might yield 
very cost-effective reductions in the global burden of many 
cancers.
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